Henry Schein (NASDAQ:HSIC) Releases Earnings Results

Henry Schein (NASDAQ:HSIC) announced its quarterly earnings data on Tuesday. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09, Briefing.com reports. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.21 billion. During the same period in the prior year, the company posted $1.21 earnings per share. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. Henry Schein updated its FY24 guidance to $5.00 to $5.16 EPS.

Henry Schein Trading Down 0.2 %

NASDAQ:HSIC traded down $0.15 during mid-day trading on Friday, reaching $73.29. The company’s stock had a trading volume of 61,347 shares, compared to its average volume of 1,098,647. Henry Schein has a twelve month low of $60.01 and a twelve month high of $82.63. The company’s fifty day simple moving average is $72.95 and its two-hundred day simple moving average is $72.35. The stock has a market cap of $9.42 billion, a P/E ratio of 23.31, a P/E/G ratio of 1.68 and a beta of 0.87. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00.

Insiders Place Their Bets

In other news, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the sale, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the sale, the insider now directly owns 209,562 shares in the company, valued at approximately $15,585,125.94. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the completion of the transaction, the chief executive officer now owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

HSIC has been the topic of several research reports. UBS Group reduced their price target on shares of Henry Schein from $82.00 to $80.00 and set a “neutral” rating on the stock in a research report on Wednesday. Leerink Partnrs reiterated a “market perform” rating on shares of Henry Schein in a research report on Monday, February 26th. Barrington Research raised their price objective on Henry Schein from $90.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday. Piper Sandler boosted their price target on Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. Finally, Jefferies Financial Group increased their price target on Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a research note on Wednesday, March 6th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Henry Schein currently has a consensus rating of “Hold” and a consensus target price of $81.73.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.